Mast Therapeutics Inc. (NYSEMKT: MSTX) has joined the Sickle Cell Disease Coalition. The Coalition brings together likeminded groups toward collective actions to improve diagnoses and treatment of sickle cell disease (SCD).
Joining SCD Coalition seems to be a strategic move by Mast Therapeutics Inc. (NYSEMKT: MSTX). The company’s drug candidate vepoloxamer is being developed as a therapy for vaso-occlusive crisis. According Mast’s CEO Brian M. Culley, vaso-occlusive crisis is a debilitating condition that occurs in people living with SCD and it can lead to early death following the damage of critical organs.
Because the SCD Coalition is also about increasing awareness of SCD and associated conditions, it could end up boosting demand for Mast’s vepoloxamer.
The size of the market
SCD reportedly affects close to 100,000 people in the U.S. and globally it affects millions of people. It is estimated that the number of people living with SCD globally will increase by 30% by 2050.
The disease is characterized by severe pain, stroke, organ failure and ultimately death – most early death.
More still needs to be done
Though important discoveries have been made to help alleviate SCD, people living with the disease still have a shorter life expectancy in addition to many complications that make their life difficult.
The other problem facing SCD patients is that many of them are unable to access the kind of care they need.
As such, SCD Coalition, which Mast Therapeutics Inc. (NYSEMKT: MSTX) has become a part of, seeks to address the various challenges faced by people living with SCD.
The American Society of Hematology (ASH) is spearheading the efforts of SCD Coalition. Members of the Coalition include researchers, policymakers, clinicians and patient groups.
As part of its contribution to the war against SCD, Mast is hoping that its candidate vepoloxamer will become the first approved therapy for vaso-occlusive crisis. Vepoloxamer is currently in Phase 3 clinical development stage.
2Q2016 highlight – Mast Therapeutics Inc. (NYSEMKT: MSTX)
Mast Therapeutics Inc. (NYSEMKT: MSTX) posted EPS loss of $0.05 in 2Q2016, indicating an improvement from EPS loss of $0.06 in the same period in 2015.